The Efficacy and Safety of Pirfenidone in Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 129 participants.
Also called NCT02932566
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 129 participants
- Sponsor
- Registry
-
NCT02932566
-
- Other papers using this trial's data
- Characteristics Associated With Growth Differentiation Factor 15 in Heart Failure With Preserved Ejection Fraction and the Impact of Pirfenidone
- Pirfenidone in heart failure with preserved ejection fraction: a randomized phase 2 trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT02932566. Randomized; quadruple masking; primary purpose treatment. Start 2017-03-02 (actual); primary completion 2019-11-29 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- The Efficacy and Safety of Pirfenidone in Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction
- Acronym
- PIROUETTE
- Condition
- Cardiac Failure
- Intervention (Drug)
- Pirfenidone
- Intervention (Drug)
- Placebo
- Lead sponsor
- Manchester University NHS Foundation Trust
- Collaborator
- National Institute for Health Research, United Kingdom
- Collaborator
- University of Manchester
- Collaborator
- University of Liverpool
- Collaborator
- Hoffmann-La Roche
Record details
- Record id
cardio:ct-nct02932566- Content hash
6763cfbd25b4e27af99619a9f168b286bc439aaef86f579a897c4d31f51bced4